Current status of diagnosis and treatment of chronic lung allograft dysfunction
10.3969/j.issn.1674-7445.2021.05.004
- VernacularTitle:慢性移植肺功能障碍的诊断与治疗现状
- Author:
Heng HUANG
1
;
Dong TIAN
Author Information
1. Heart and Lung Transplant Research Laboratory, Affiliated Hospital of North Sichuan Medical College, Academician (Expert) Workstation, Affiliated Hospital of North Sichuan Medical College, Medical Imaging Key Laboratory of Sichuan Province, North Sichuan Medical College, Nanchong 637000, China
- Publication Type:Research Article
- Keywords:
Lung transplantation;
Chronic lung allograft dysfunction;
Bronchiolitis obliterans syndrome;
Restrictive allograft syndrome;
Donor-derived cell-free DNA;
Azithromycin;
Montelukast;
Pirfenidone
- From:
Organ Transplantation
2021;12(5):525-
- CountryChina
- Language:Chinese
-
Abstract:
Chronic lung allograft dysfunction (CLAD) is the largest obstacle to the long-term survival of lung transplant recipients, which represents a series of complicated clinical manifestations of significant and persistent deterioration of lung allograft function after surgery. Due to lack of effective strategies for early diagnosis and prevention, over half of lung transplant recipients will develop CLAD within postoperative 5 years, which is likely to increase to 75% within postoperative 10 years. At present, no drug can be administered to completely prevent or reverse the progression of CLAD. In recent years, since the definition, diagnosis and treatment of CLAD have been updated by International Society of Heart and Lung Transplantation (ISHLT) in 2019, the understanding of CLAD has been significantly deepened within the international community. In this article, comprehensive diagnostic methods and potential treatment strategies of CLAD were explicitly illustrated, aiming to provide theoretical reference and insights for early monitoring and management of the incidence and progression of CLAD.
